TY - JOUR
T1 - Real-world comorbidities of atopic dermatitis in the pediatric ambulatory population in the United States
AU - Huang, Amy H.
AU - Roh, Youkyung Sophie
AU - Sutaria, Nishadh
AU - Choi, Justin
AU - Williams, Kyle A.
AU - Canner, Joseph K.
AU - Grossberg, Anna L.
AU - Kwatra, Shawn G.
N1 - Funding Information:
Funding sources: Dr Kwatra is supported by grant funding from Pfizer, Inc, the Skin of Color Society and a Dermatology Foundation Medical Dermatology Career Development Award.Dr Kwatra is an advisory board member or consultant for Abbvie, Incyte Corporation, Galderma, Pfizer, Inc, Regeneron Pharmaceuticals, and Menlo Therapeutics and has received grant funding from Galderma SA, Kiniksa Pharmaceuticals, and Pfizer Inc. He is also a recipient of a Dermatology Foundation Medical Dermatology Career Development Award. The other authors have no conflicts of interest to declare.
Funding Information:
Funding sources: Dr Kwatra is supported by grant funding from Pfizer , Inc, the Skin of Color Society and a Dermatology Foundation Medical Dermatology Career Development Award .
Publisher Copyright:
© 2021 American Academy of Dermatology, Inc.
PY - 2021/10
Y1 - 2021/10
N2 - Background: Increasing evidence has suggested the systemic nature of atopic dermatitis (AD), a common inflammatory skin condition in children. However, comprehensive analyses of real-world comorbidities in pediatric AD are limited. Objective: To characterize comorbidity burden in patients with AD aged <18 years old. Methods: The MarketScan commercial claims database was queried from January 1, 2017, to December 31, 2017. Age- and sex-matched analyses were used to compare patients with AD with general population controls. Results: A total of 86,969 pediatric patients with AD and 116,564 matched controls were identified. Increased anxiety (odds ratio [OR], 1.20) and attention-deficit hyperactivity disorder (OR, 1.11) were noted in patients with AD. In addition to dermatologic/allergic diseases, AD was also associated with infections, including methicillin-resistant Staphylococcus aureus (OR, 3.76), and autoimmune conditions, including vitiligo (OR, 2.98) and alopecia areata (OR, 4.32). Pediatric patients with AD had higher likelihoods of lymphoid/hematologic malignancies (OR, 1.94), ocular disorders (OR, 1.37-2.02), metabolic syndrome (OR, 1.61), and obesity (OR, 1.81). For all the ORs mentioned above, P was <.001. Limitations: Retrospective analysis of health care claims data. Conclusions: AD in pediatric patients was associated with a wide range of psychologic and systemic comorbidities. Increased awareness can help minimize its negative effects on the quality of life and prevent long-term health consequences in young patients with AD.
AB - Background: Increasing evidence has suggested the systemic nature of atopic dermatitis (AD), a common inflammatory skin condition in children. However, comprehensive analyses of real-world comorbidities in pediatric AD are limited. Objective: To characterize comorbidity burden in patients with AD aged <18 years old. Methods: The MarketScan commercial claims database was queried from January 1, 2017, to December 31, 2017. Age- and sex-matched analyses were used to compare patients with AD with general population controls. Results: A total of 86,969 pediatric patients with AD and 116,564 matched controls were identified. Increased anxiety (odds ratio [OR], 1.20) and attention-deficit hyperactivity disorder (OR, 1.11) were noted in patients with AD. In addition to dermatologic/allergic diseases, AD was also associated with infections, including methicillin-resistant Staphylococcus aureus (OR, 3.76), and autoimmune conditions, including vitiligo (OR, 2.98) and alopecia areata (OR, 4.32). Pediatric patients with AD had higher likelihoods of lymphoid/hematologic malignancies (OR, 1.94), ocular disorders (OR, 1.37-2.02), metabolic syndrome (OR, 1.61), and obesity (OR, 1.81). For all the ORs mentioned above, P was <.001. Limitations: Retrospective analysis of health care claims data. Conclusions: AD in pediatric patients was associated with a wide range of psychologic and systemic comorbidities. Increased awareness can help minimize its negative effects on the quality of life and prevent long-term health consequences in young patients with AD.
KW - MarketScan
KW - atopic dermatitis
KW - comorbidities
KW - eczema
KW - pediatric
UR - http://www.scopus.com/inward/record.url?scp=85104421638&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104421638&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2021.03.016
DO - 10.1016/j.jaad.2021.03.016
M3 - Article
C2 - 33689777
AN - SCOPUS:85104421638
SN - 0190-9622
VL - 85
SP - 893
EP - 900
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 4
ER -